title: Combination of adjuvants: the future of vaccine design.
abstract: It is thought that the development of vaccines for the treatment of infectious diseases and cancer is likely to be achieved in the coming decades. This is partially due to a better understanding of the regulatory networks connecting innate with adaptive immune responses. The innate immune response is triggered by the recognition of conserved pathogen-associated molecular patterns by germ line-coded pattern recognition receptors. Several families of pattern recognition receptors have been characterized, including Toll-like receptors and nucleotide-binding domain receptors. The identification of their ligands has driven the development of novel adjuvants many of which have been tested in vaccine clinical trials. Here, the authors review recent preclinical data and clinical trial results supporting the view that combinations of adjuvants are the way forward in vaccine design. Multiadjuvanted vaccines can stimulate the broad and robust protective immune responses required to fight chronic infectious diseases and cancer.
authors.affiliation: CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia.
authors.forename: Adele
authors.initials: A
authors.lastname: Mount
authors.forename: Sandra
authors.initials: S
authors.lastname: Koernig
authors.forename: Anabel
authors.initials: A
authors.lastname: Silva
authors.forename: Debbie
authors.initials: D
authors.lastname: Drane
authors.forename: Eugene
authors.initials: E
authors.lastname: Maraskovsky
authors.forename: Adriana Baz
authors.initials: AB
authors.lastname: Morelli
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D014611:Vaccination / Q000379:methods*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D014612:Vaccines